Cardiovascular diseases (CVD) are the major health issue of modernized society with a high mortality rate. Lifestyle, genetic makeup, and diet are some of the major influencing factors associated with CVD. The dyslipidemia is one such factor related to the development of several CVD. Many studies proved that the consumption of probiotics confers several health benefits. Several studies reported the evaluation of the cholesterol-lowering ability of probiotics (probiotics that showed positive effect in vitro and in vivo studies) in human volunteers. The current review summarizes the outcomes of human studies on the cholesterol-lowering property of probiotics. Probiotic consumption significantly improved the health status of hypercholesteremic patients by reducing the low-density lipoprotein cholesterol, total cholesterol, triglyceride levels, and increased the high-density lipoprotein cholesterol. The probiotic supplementation improved the lipid profile of diabetic patients, and obese people as well. However, not all probiotic interventions are effective against dyslipidemia. The results are controversial and depend on several factors such as probiotic strain, dose, duration of the treatment, lifestyle changes, etc. This literature survey indorses additional studies on the cholesterol-lowering property of probiotics, which could help to reduce the risk of CVD and other dyslipidemia associated health issues.
Introduction
Cardiovascular disease (CVD) is one of the major health issues with a high mortality rate (~17.7 million deaths/year) [1] . The medical expenses to manage the CVDs are predicted to be tripled by 2030 [2] . Though genetics, microbiome, diet, lifestyle, and metabolic syndrome are the factors associated with the development of CVD, dyslipidemic condition (characterized by the elevated level of low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and the reduction in high-density lipoprotein cholesterol (HDL-C) level), is one of the major risk factor related to CVD incidences [3] .
The alteration of gut microbiota is closely associated with several ill-health conditions. High fatand sugar-containing diet, and low dietary fiber have a negative impact on the gastrointestinal system [4] . Several studies revealed the link between gut microbiota and CVD incidences and progress [5, 6] . Lower abundance of Bacteroidetes, higher abundance of Lactobacillales, Enterobacteriaceae, Streptococcus spp., and increased Firmicutes/Bacteroidetes ratio are associated with CVD [6] . The healthy dietary preference (rich in vegetables, fibers, and low consumption of meat and refined food products) could improve gut health and reduce the risk of CVD.
Probiotics are live microbes that exhibit beneficial effect on human health when consumed in a suitable amount [7] . Microbes that possess several health beneficial effects are termed as probiotics
Impact of Probiotic Supplementation on the Lipid Profile of the Human Subjects

Hypercholesterolemic Subjects
Cavallini et al. [24] studied the effect of probiotics (Enterococcus faecium CRL 183 and Lactobacillus helveticus 416) fermented soy product containing isoflavone on the lipid profile of moderately hypercholesterolemic male subjects. The supplementation of soy product (equivalent of 10 10 CFU of probiotic strain) with 50 mg isoflavone per day for 42 days significantly improved the total cholesterol (TC), LDL-C (low-density lipoprotein-cholesterol) and electronegative LDL content in the subjects while the level of HDL-C (high-density lipoprotein-cholesterol) was unaffected and the level of fibrinogen and C-reactive protein levels were not enhanced. The results suggested that the consumption of probiotic soy product with isoflavone improved the cardiovascular risk factors in hypercholesterolemic subjects [24] .
A 12-week supplementation of a mixture of L. plantarum strains (CECT 7528, CECT 7529, CECT 7527; 10 10 CFU/day) significantly increased the level of HDL-C and reduced LDL-C, TC, triglycerides (TG), LDL-C/HDL-C ratio, and oxidized LDL levels in hypercholesterolemic subjects. The results revealed that probiotics could be used for hypercholesterolemia treatment [25] .
The dyslipidemic children were supplemented with a mixture of Bifidobacterium strains (B. animalis lactis MB 2409, B. longum BL04, and B. bifidum MB 109B) for three months and their diet was monitored. After the intervention, the changes in lipid profile were measured. The concentration of serum level TC (222.8 ± 23.2 to 211.9 ± 27.3 mg/dL), HDL-C (55.8 ± 12.2 to 60.7 ± 14.2 mg/dL), TG (99.0 ± 61.7 to 79.5 ± 34.5 mg/dL), and LDL-C (147.2 ± 21.9 to 135.3 ± 24.2 mg/dL) were significantly improved after three months of probiotic supplementation when compared to the baseline values. The TC and LDL-C levels were notably reduced in the probiotic group compared to that of the placebo. The results suggested that the supplementation of probiotics with dietary restriction help to improve the lipid profile in dyslipidemic children [26] .
The consumption of single probiotic strain (E. faecium M-74; 2 × 10 9 CFU/day) and selenium (50 µg) for one year did not alter the level of HDL-C and TG, while it significantly reduced the TC, and LDL-C in elderly people compared to baseline and to that of the placebo. The study results recommend that probiotics are promising therapeutic agents for several human ill-health conditions [27] .
The intervention of probiotic capsule containing L. acidophilus and B. bifidum (10 9 CFU/capsule; three capsule/day) for six weeks significantly reduced the TC and LDL-C level in hypercholesterolemic patients. There was no change in TG and blood sugar levels of the patients. The level of HDL-C was significantly reduced during the study period. However, the probiotic supplements improved the cholesterol profile, and the HDL-C content also reduced. The authors claimed that L. acidophilus and B. bifidum have the potential to lower cholesterol in hypercholesterolemic patients [28] .
A significant level of reduction (15.5%) in remnant lipoprotein particle (RLP-P) content was observed in the hypercholesterolemic patients, who had probiotic supplementation (Saccharomyces cerevisiae var. boulardii CNCM I-1079) for eight weeks. The consumption of four probiotic capsules (1.4 × 10 9 CFU/capsule) twice per day does not alter the TC, LDL-C, very low-density lipoprotein-particle (VLDL-P), HDL-C, TG level, insulin, and representative cardiovascular markers, significantly, but the notable level of RLP-P reduction was recorded after the experimental period. The results suggested that CNCM I-1079 supplementation could be used as an adjuvant for preventing and treating coronary artery disease [29] .
Healthy Subjects
The supplementation of a milk-based fruit drink containing probiotic strain L. rhamnosus GG (6.2 × 10 7 CFU/ ml; 250 ml per day for three weeks) positively altered the global lipid profile in healthy volunteers. Particularly, the level of sphingomyelins, lysophosphatidylcholines, and glycerophosphatidylcholines were reduced after probiotic supplementation while triacylglycerols content was increased when compared to baseline and to that of the placebo. The study also revealed the association of inflammatory cytokines and lipid profile changes upon probiotic intervention. The results proved that the intervention of L. rhamnosus GG improves the lipid profile in healthy subjects [30] .
The supplementation of 30 g of probiotic cheese containing L. acidophilus LA5 and B. lactis BB12 (each 5 × 10 6 CFU) with or without 30 g of chicory root extract significantly reduced the TC and LDL-C and increased the HDL-C content in healthy volunteers in seven weeks of the experimental period. The level of TG was reduced at a notable level in group supplemented with probiotics and chicory root extract. There was no change in anthropometric measurements of the volunteers after the experimental period when compared to baseline measurements. The study claimed that the use of probiotic cheese containing LA5 and BB12 along with chicory root extract might be used to treat and prevent the dyslipidemic condition [31] .
Diabetes Patients
The consumption of probiotic yogurt (300 g per day) containing L. acidophilus La5 (~4.14 × 10 6 CFU/g) and B. lactis Bb12 (~3.61 × 10 6 CFU/g) for six weeks significantly improved the lipid profile of type 2 diabetes mellitus (T2D) patients. Specifically, the level of TC, LDL-C, and ratio of LDL-C:HDL-C and TC:HDL-C were reduced significantly when compared to baseline and to that of the placebo control. There was no change in HDL-C and TG content in studied subjects. The results suggested that the regular consumption of probiotic yogurt could improve the cholesterol level of T2D patients [32] .
The supplementation of probiotic capsule containing L. acidophilus, L. casei, and B. bifidum (each 2 × 10 9 CFU/g) for six weeks reduced the TG and VLDL-C content in gestational diabetic (GD) patients while no changes were observed in LDL-C, HDL-C, and TC. The probiotic supplementation improved the serum insulin, plasma glucose level, homeostasis model assessment for insulin resistance (HOMA-IR), and insulin sensitivity when compared to that of the placebo. The consumption of a probiotic capsule enhanced the glycemic control and slightly improved the lipid profile of GD patients [33] .
The consumption of fermented milk containing B. animalis subsp. lactis BB-12 and L. acidophilus La-5 (each 10 9 CFU; 120 g of fermented milk) for six weeks significantly reduced the LDL-C and TC content in T2D patients. Additionally, the probiotic group showed reduced inflammatory cytokines level and metabolic parameters such as HOMA-IR, HbA1c, fructosamine, and fasting blood glucose (FBG). The study concluded that the probiotic consumption amended the glycemic control, inflammatory system, and lipid profile in T2D subjects [34] .
The daily consumption of 200 mL of fermented soymilk containing 2 × 10 7 CFU/mL of L. plantarum A7 for eight weeks significantly reduced the TC, TG, LDL-C, and non-HDL-C in T2D patients while HDL-C content was not altered when compared to baseline and to that of the control group. The serum genistein and estimated glomerular filtration rate (eGFR) values were increased in the probiotic soymilk-supplemented group when compared to the non-probiotic soymilk group. The results suggested that L. plantarum A7 fermented soymilk showed a favorable impact on glomerular function and lipid profile of T2D subjects [35] .
The supplementation of 6 g/day of probiotic preparation made with L. acidophilus, B. bifidum, B. lactis, and B. longum (each 1.5 × 10 9 CFU) for 24 weeks reduced the occurrence of low-HDL-C and increased the HDL-C content when compared to the placebo control. The parameters associated with hyperglycemia, hypertension, and metabolic syndrome have also been reduced significantly in the probiotic group compared to that of the placebo control group [36] .
The consumption of multi-species probiotic preparation (L. acidophilus ZT-L1, L. reuteri ZT-Lre, L. fermentum ZT-L3, and B. bifidum ZT-B1; 2 × 10 9 CFU/day) for 12 weeks significantly reduced the TG, TC:HDL-C ratio, and increased the HDL-C level in diabetic nephropathy (DN) patients compared to that of the placebo control. The increase in insulin sensitivity and plasma total glutathione, and decrease in FBG, HOMA-IR values, and malondialdehyde, high-sensitive C-reactive protein were observed in the probiotic-treated group. The results suggested that probiotic consumption improved the cardiovascular diseases risk factors in DN patients [37] .
The supplementation of Ecologic ® Barrier (multi-strain probiotic preparation containing B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19, and Lactococcus lactis W58; dosage: two doses per day) for six months reduced the TG, TC, LDL-C, and TC:HDL-C ratio values significantly when compared to the placebo and baseline values. Ecologic ® Barrier supplementation also reduced the FBG, insulin, HOMA-IR values, and inflammatory cytokines level in T2D patients. The results suggested that multi-strain probiotic preparation could be an adjuvant therapeutic agent to improve diabetic and cardiovascular-associated metabolic parameters [38] .
Other Subjects
The supplementation of Ecologic ® Barrier (2.5 × 10 9 or 1 × 10 10 CFU/day) for 12 weeks improved the TG and LDL-C content and other metabolic and cardiovascular disease parameters in obese postmenopausal women [39] .
The supplementation of B. breve B-3 capsules (2 × 10 10 CFU/day) for 12 weeks slightly reduced the TG and improved the HDL-C content in pre-obese subjects, but the changes are not significant when compared to baseline values. However, the probiotic supplementation reduced the body fat in healthy pre-obese subjects; and the lipid profile was not improved significantly [40] . Similarly, L. gasseri BNR17 supplementation (10 9 or 10 10 CFU/day) for 12 weeks reduced the visceral fat mass in obese subjects, but the changes in the TC, LDL-C, HDL-C, and TG were not significant when compared to the placebo control [41] . The results have been summarized in Table 1 . 
Meta-Analysis Studies
Several meta-analysis studies have been published based on the effect of probiotic supplementation on the lipid profile of human subjects. The probiotic supplementation (both in the form of freeze-dried powder, fermented products) significantly reduced TC and LDL-C in hypercholesterolemic subjects while no significant changes were observed in TG and HDL-C content [42] [43] [44] [45] [46] . The sub-group analysis of clinical trials suggested that the long-term consumption of probiotic exhibited more beneficial effects on the lipid profile of the subjects [44] . A recent study reported that intervention of probiotics significantly reduced the TC when compared to the TC of the control group, and also stated that specific probiotic strains (B. lactis and L. acidophilus; L. plantarum) significantly reduced the TC [47] . Another recent study suggested that the probiotic preparations containing Lactobacillus and Bifidobacterium could reduce the LDL-C content in metabolic syndrome patients without improving the TC and HDL-C content [48] .
Probiotic consumption improved the TC and HDL-C content in non-alcoholic fatty liver disease (NAFLD) subjects, but no changes were found to be observed in the level of LDL-C. The study claimed that there were no sufficient studies on the impact of probiotic consumption on NAFLD to confirm the beneficial role of probiotics [49] .
The probiotic interventions significantly improved the lipid profile (reduced the TC, LDL-C, and TG) of T2D patients along with the glucose homeostasis effectively [50] [51] [52] .
Collectively, the results of meta-analysis revealed that the supplementation of probiotics might improve the lipid profile of the human subjects. The efficiency of the probiotic intervention hinges on several factors like dosage, duration of the treatment, combination of the probiotics strains, strain quality, host metabolic activities, host-microbiome, etc. Thus, all the probiotic formulations are effective in conferring the beneficial effects on the host system. The non-significant outcomes of probiotic intervention studies are detailed in the following section.
Effect of Probiotics Supplementation on Lipid Profile: Non-Significant Outcomes
The consumption of L. acidophilus (9 × 10 10 CFU/ day for six weeks), B. animalis subsp. lactis BB-12 ® (3.16 × 10 9 CFU/day for four weeks), probiotic yogurt containing both L. acidophilus and BB-12 ® (3.0 × 10 9 CFU/day for seven days), and L. acidophilus and B. longum (each 10 10 CFU/ day for two months) did not amend the lipid profile in healthy human subjects [53] [54] [55] [56] .
Recently, Culpepper et al. [57] reported that the supplementation of B. subtilis R0179 (2.5 × 10 9 CFU), B. animalis subsp. lactis B94 (5 × 10 9 CFU) for six weeks does not have any influential effect on the lipid profile of healthy obese subjects.
A multi-genus and multi-species probiotic formula (L. acidophilus, L. casei, L. rhamnosus, L. bulgaricus, B. breve, B. longum, and Streptococcus thermophilus) supplementation for eight weeks showed no improvement in the lipid profile of T2D patients [58] . Mahboobi et al. [59] noticed that the consumption of a multi-species probiotic capsule did not alter the TC, LDL-C, HDL-C, or TG values in pre-diabetic subjects when compared to baseline and to that of the placebo control. Similarly, the supplementation of probiotic (Lactobacillus spp., Bifidobacterium spp., S. thermophilus) or synbiotic formulation (probiotics and fructo-oligosaccharide) did not amend the lipid profile of T2D patients [60, 61] .
A multi-species probiotic preparation containing four Lactobacillus spp. (L. acidophilus, L. bulgaricus, L. bifidum, and L. casei) did not improve the lipid profile in T2D patients. Only a non-significant increase in HDL-C level was observed in the experimental subjects [62] . Similarly, 12 weeks of the randomized controlled clinical study suggested that the Ecologic ® Barrier supplementation did not improve the lipid profile in T2D patients [63] .
Opinion on the Hypocholesterolemic Effect of Reviewed Probiotics
Based on the randomized, placebo-controlled, double-blind studies [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] reviewed in the present article, the hypocholesterolemic effect of the probiotics was not significantly influenced by the diet. Studies reported based on the intervention of single-strain probiotic (E. faecium M-74 along with selenium [27] ; Saccharomyces cerevisiae var. boulardii CNCM I-1079 [29] ; L. rhamnosus GG [30] ; Soy milk containing L. plantarum A7 [35] ) preparation showed significant hypocholesterolemic effect when compared to the study reported with the intervention of single-strain probiotics (B. breve B-3 [40] ; Lactobacillus gasseri BNR17 [41] ) preparation; whereas intervention of single-strain probiotics (L. acidophilus [53] ; B. animalis subsp. lactis BB-12 [54] ) preparation exhibited no beneficial effect on the lipid profile of the studied subjects. Therefore, the level of improving lipid profile is strain-specific and might depend on the dosage and duration of the intervention.
Studies based on the intervention of multi-genus, multi-species, multi-strain (strains of same species) probiotic preparation has been reported with positive effect on lipid profile [24] [25] [26] 28, [31] [32] [33] [34] [36] [37] [38] [39] 47, 48] , while several studies reported no effect of multi-genus and multi-species probiotic intervention on the lipid profile [55] [56] [57] [58] [59] [60] [61] [62] [63] . Even though intervention of Ecologic ® Barrier (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19 and W58) exhibit hypocholesterolemic effect on different subjects (individuals with T2D [38] ; obese postmenopausal women [39] ) with different intervention duration (six months [38] ; 12 weeks [39] ), dosage of probiotic mixture does not influence the cholesterol-lowering ability of the probiotic mixture.
The intervention of fermented milk with L. acidophilus LA-5 and B. animalis subsp. lactis BB-12 investigated in two studies [32, 34] with the same intervention duration (six weeks) showed a significant level of hypocholesterolemic effect in the individuals (almost similar age groups) with T2D; whereas intervention of the same probiotic mixture along with chicory root extract [31] showed significant hypocholesterolemic effect in the healthy subjects even with low dosage of probiotic mixture [31] (when compared to the dosage of probiotic mixture in other studies [32, 34] ), which might be due to the duration of intervention (seven weeks) or effect of chicory root extract or depend on the healthy host. Hence, apart from dosage, the duration of intervention plays an important role in influencing the curative effect of probiotics. Therefore, regular consumption of probiotic preparation is required to retain health benefits in the needed host.
Concluding Remarks
Several studies reported the effect of probiotics on lipid profiles such as TC, TG, LDL-C, and HDL-C levels in different diseased conditions and in healthy volunteers as well, but the results are not conclusive or consistent. The results of the studies suggested that the cholesterol-lowering ability of probiotics is strain-specific, and depends on the host. Studies proposed that the hypocholesterolemic effect of probiotics rely on the bile salt hydrolase activity, production of SCFAs, binding of cholesterol to the cell surface of probiotic, co-precipitation of cholesterol and bile, and conversion of cholesterol into coprostanol of probiotic strain [64] .
Some of the human clinical studies have limitations such as probiotic formulations, dosage, duration of the treatment and washout period, no proper follow-up study, etc. Most of the study results conveyed that none of the probiotic supplements have the ability to improve all the desirable parameters, except in some cases. Several probiotics exhibited hypocholesterolemic effect by lowering the TC, LDL-C, and TG levels, and by improving the HDL-C levels in individuals with hypercholesterolemia. The literature survey made in this study suggested that the cholesterol-lowering ability of a probiotic formulation greatly influenced by the factors such as strains of the same bacterial species showed different results, the combination of strains, dose, and duration. Intake of probiotics in capsule form is considered to be more effective in exhibiting beneficial effects. Diet does not significantly influence the cholesterol-lowering ability of the probiotics. Several meta-analyses revealed that the supplementation of probiotic formulations improved the lipid profile. Based on the meta-analysis studies, specific probiotic strains such as B. lactis and L. acidophilus, L. plantarum significantly reduced the TC in adult patients [47] , and Lactobacillus and Bifidobacterium reduced LDL-C levels in metabolic syndrome patients [48] . Apart from dosage, the intervention duration plays a role in impacting the curative effects of probiotics; thus, regular consumption of probiotic is required to retain health benefits. Further studies are necessary to formulate the probiotic-based therapeutic supplements to control dyslipidemia and to prevent the incidence of CVD.
